ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

72.18 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm

January 07, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

3 Reasons to Avoid ANIP and 1 Stock to Buy Instead

January 04, 2026

Since January 2021, the S&P 500 has delivered a total return of 83.6%. But one standout stock has nearly doubled the market - over the past five years, ANI Pharmaceuticals has surged 147% to $77.55 per...

Via StockStory

Topics Stocks Supply Chain

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗

December 28, 2025

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Via The Motley Fool

Topics Regulatory Compliance

6 Analysts Have This To Say About ANI Pharmaceuticals ↗

September 24, 2025

Via Benzinga

4 Analysts Have This To Say About ANI Pharmaceuticals ↗

September 08, 2025

Via Benzinga

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over...

Via StockStory

Topics Stocks

3 Small-Cap Stocks We’re Skeptical Of

December 10, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

1 Russell 2000 Stock to Consider Right Now and 2 We Avoid

November 18, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals’s Q3 Earnings Call

November 14, 2025

ANI Pharmaceuticals delivered a third quarter marked by substantial year-over-year growth, with management attributing performance to strong momentum across its Rare Disease and Generics segments. CEO...

Via StockStory

Topics Earnings

Generic Pharmaceuticals Stocks Q3 Recap: Benchmarking ANI Pharmaceuticals (NASDAQ:ANIP)

November 11, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best

November 11, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time ↗

November 10, 2025

The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time

Via The Motley Fool

ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook

November 08, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The...

Via StockStory

ANI PHARMACEUTICALS INC (NASDAQ:ANIP) Reports Record Q3 2025 Earnings, Beating Estimates ↗

November 07, 2025

ANI Pharmaceuticals (ANIP) smashed Q3 2025 earnings estimates, posting record revenue and a 14% EPS beat. The company also raised its full-year 2025 guidance.

Via Chartmill

ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Strong Q3 Numbers, Stock Soars

November 07, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The...

Via StockStory

Examining the Future: ANI Pharmaceuticals's Earnings Outlook ↗

November 06, 2025

Via Benzinga

ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect

November 05, 2025

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For November 7, 2025 ↗

November 07, 2025

Via Benzinga

3 Profitable Stocks We’re Skeptical Of

October 27, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Screens as High Growth Momentum Stock Meeting Minervini Trend Template ↗

October 20, 2025

ANI Pharmaceuticals (ANIP) combines strong technical uptrend with explosive earnings and sales growth, fitting a proven strategy for spotting potential market leaders.

Via Chartmill

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Combines Strong Growth Momentum with Bullish Technical Setup ↗

October 13, 2025

ANI Pharmaceuticals (ANIP) shows strong growth momentum with 76% EPS growth and a positive technical setup, signaling a potential breakout opportunity.

Via Chartmill

ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q2 Earnings?

October 07, 2025

ANI Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 37.4% to $92.06 per share while the index has...

Via StockStory

Topics Stocks Supply Chain

3 Low-Volatility Stocks We’re Skeptical Of

September 29, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

3 Small-Cap Stocks We Approach with Caution

September 23, 2025

Via StockStory

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Presents a High Growth Momentum and Technical Breakout Opportunity ↗

September 20, 2025

ANI Pharmaceuticals (ANIP) shows strong earnings acceleration, robust sales growth, and bullish analyst revisions. With a top technical rating, it's forming a base near highs, signaling a potential...

Via Chartmill

September 18, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

3 Russell 2000 Stocks with Questionable Fundamentals

September 17, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Via StockStory

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack

September 04, 2025

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Generic Pharmaceuticals Stocks Q2 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Best of the Bunch

September 01, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

ANI Pharmaceuticals Inc (NASDAQ:ANIP) Shows Strong Momentum and Growth, Fitting Minervini's Trend-Following Criteria ↗

August 28, 2025

ANI Pharmaceuticals (ANIP) shows strong technical momentum and accelerating earnings growth, making it a compelling candidate for high-growth momentum investors.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.